皮肤性病诊疗学杂志2026，Vol.33Issue(1)：72-80,封3,10.DOI:10.3969/j.issn.1674-8468.2026.01.012
度普利尤单抗在非特应性皮炎皮肤病中的应用进展
Progress in the application of dupilumab for non-atopic dermatitis
摘要
Abstract
Dupilumab inhibits Th2-mediated inflammatory responses by specifically blocking the signaling pathways of interleukin-4 and interleukin-13.Recently,in addition to its approved indication for the treatment of moderate-to-severe atopic dermatitis,dupilumab has also shown effi-cacy in treating other inflammatory skin diseases,such as prurigo nodularis,bullous pemphigoid,chronic spontaneous urticaria,allergic contact dermatitis,nummular eczema,chronic hand ecze-ma,chronic actinic dermatitis,lichen amyloidosis,chronic pruritus,cutaneous immune-related adverse events,eosinophilic pustular folliculitis,alopecia areata,keloids,and some genetic skin diseases.This article reviews the progress of dupilumab in the treatment of non-atopic dermatitis skin diseases to provide more theoretical basis and treatment options for the clinicians.关键词
炎症性皮肤病/度普利尤单抗/白细胞介素-4/白细胞介素-13Key words
inflammatory skin diseases/dupilumab/interleukin-4/interleukin-13引用本文复制引用
史希武,刘晴,王秀丽,韩杨,胡竹林..度普利尤单抗在非特应性皮炎皮肤病中的应用进展[J].皮肤性病诊疗学杂志,2026,33(1):72-80,封3,10.基金项目
安徽省卫生健康科研项目(AHWJ2023A30066) （AHWJ2023A30066）
